Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
A Study to Test the Pharmacokinetics Efficacy and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures

The purpose of the study is to evaluate the pharmacokinetics (PK) of brivaracetam (BRV) in neonates who have seizures that are not adequately controlled with previous antiepileptic drug (AED

  • 1 views
  • 03 Jul, 2021
  • 16 locations
A Study to Evaluate the Efficacy Safety and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE

  • 0 views
  • 22 Jul, 2021
  • 3 locations
A Study to Test the Safety and Tolerability of Brivaracetam in Pediatric Study Participants With Seizures

The purpose of the study is to evaluate the long-term safety and tolerability of brivaracetam.

antiepileptics
brivaracetam
seizure
electroencephalogram
  • 0 views
  • 21 Jul, 2021
  • 21 locations
A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy

The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in subjects (>=16 to 80 years of age) with partial seizures with

brivaracetam
vagus nerve stimulation
antiepileptics
partial seizure
seizure
  • 840 views
  • 16 Jul, 2021
  • 111 locations
Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury

Spinal cord injury (SCI) is associated with severe neuropathic pain that is often refractory to all pharmacological intervention. Preliminary data suggest brivarecetum is a mechanism-based pharmacological intervention for neuropathic pain in SCI. This randomized, placebo-controlled pilot clinical trial will assess feasibility of a 3-month treatment course with brivarecetum.

  • 0 views
  • 08 May, 2021
  • 2 locations
Brivaracetam: a Prospective and Multicentre Post-marketing Observational Study

Brivaracetam (BRV) is a new antiepileptic drug approved in March 2016 by Health Canada for the adjunctive treatment of focal epilepsy in adults. While randomized controlled trials represent the

brivaracetam
convulsive seizure
adjunctive treatment
neurological disorder
partial epilepsy
  • 0 views
  • 24 Jan, 2021
  • 1 location